Loading [Contrib]/a11y/accessibility-menu.js
Perspective Special Issues

The Role of the WI-38 Cell Strain in Saving Lives and Reducing Morbidity

  • The modern success story of vaccinations involves a historical chain of events that transformed the discovery that vaccines worked, to administering them to the population. We estimate the number of lives saved and morbidity reduction associated with the discovery of the first human cell strain used for the production of licensed human virus vaccines, known as WI-38. The diseases studied include poliomyelitis, measles, mumps, rubella, varicella (chicken pox), herpes zoster, adenovirus, rabies and Hepatitis A. The number of preventable cases and deaths in the U.S. and across the globe was assessed by holding prevalence rates and disease-specific death rates constant from 1960–2015. Results indicate that the total number of cases of poliomyelitis, measles, mumps, rubella, varicella, adenovirus, rabies and hepatitis A averted or treated with WI-38 related vaccines was 198 million in the U.S. and 4.5 billion globally (720 million in Africa; 387 million in Latin America and the Caribbean; 2.7 billion in Asia; and 455 million in Europe). The total number of deaths averted from these same diseases was approximately 450,000 in the U.S., and 10.3 million globally (1.6 million in Africa; 886 thousand in Latin America and the Caribbean; 6.2 million in Asia; and 1.0 million in Europe).

    Citation: S. J. Olshansky, L. Hayflick. The Role of the WI-38 Cell Strain in Saving Lives and Reducing Morbidity[J]. AIMS Public Health, 2017, 4(2): 127-138. doi: 10.3934/publichealth.2017.2.127

    Related Papers:

    [1] Terri Rebmann, Kristin D. Wilson, Travis Loux, Ayesha Z. Iqbal, Eleanor B. Peters, Olivia Peavler . Outcomes, Approaches, and Challenges to Developing and Passing a Countywide Mandatory Vaccination Policy: St. Louis County’s Experience with Hepatitis A Vaccine for Food Service Personnel. AIMS Public Health, 2016, 3(1): 116-130. doi: 10.3934/publichealth.2016.1.116
    [2] Maria Mercedes Ferreira Caceres, Juan Pablo Sosa, Jannel A Lawrence, Cristina Sestacovschi, Atiyah Tidd-Johnson, Muhammad Haseeb UI Rasool, Vinay Kumar Gadamidi, Saleha Ozair, Krunal Pandav, Claudia Cuevas-Lou, Matthew Parrish, Ivan Rodriguez, Javier Perez Fernandez . The impact of misinformation on the COVID-19 pandemic. AIMS Public Health, 2022, 9(2): 262-277. doi: 10.3934/publichealth.2022018
    [3] Sheikh Mohd Saleem, Sudip Bhattacharya . Reducing the infectious diseases burden through “life course approach vaccination” in India—a perspective. AIMS Public Health, 2021, 8(3): 553-562. doi: 10.3934/publichealth.2021045
    [4] Henry V. Doctor . Assessing Antenatal Care and Newborn Survival in Sub-Saharan Africa within the Context of Renewed Commitments to Save Newborn Lives. AIMS Public Health, 2016, 3(3): 432-447. doi: 10.3934/publichealth.2016.3.432
    [5] Akari Miyazaki, Naoko Kumada Deguchi, Tomoko Omiya . Difficulties and distress experienced by Japanese public health nurses specializing in quarantine services when dealing with COVID-19: A qualitative study in peri-urban municipality. AIMS Public Health, 2023, 10(2): 235-251. doi: 10.3934/publichealth.2023018
    [6] Peng Wang, Zhenyi Li, Alice Jones, Michael E. Bodner, Elizabeth Dean . Discordance between lifestyle-related health behaviors and beliefs of urban mainland Chinese: A questionnaire study with implications for targeting health education. AIMS Public Health, 2019, 6(1): 49-66. doi: 10.3934/publichealth.2019.1.49
    [7] Safaa Badi, Loai Abdelgadir Babiker, Abdullah Yasseen Aldow, Almigdad Badr Aldeen Abas, Mazen Abdelhafiez Eisa, Mohamed Nour Abu-Ali, Wagass Abdelrhman Abdella, Mohamed Elsir Marzouq, Musaab Ahmed, Abubakr Ali M Omer, Mohamed H Ahmed . Knowledge and attitudes toward COVID-19 vaccination in Sudan: A cross-sectional study. AIMS Public Health, 2023, 10(2): 310-323. doi: 10.3934/publichealth.2023023
    [8] Samer A Kharroubi, Marwa Diab-El-Harake . Sex differences in COVID-19 mortality: A large US-based cohort study (2020–2022). AIMS Public Health, 2024, 11(3): 886-904. doi: 10.3934/publichealth.2024045
    [9] Niclas Olofsson . A life course model of self-reported violence exposure and illhealth with a public health problem perspective. AIMS Public Health, 2014, 1(1): 9-24. doi: 10.3934/publichealth.2014.1.9
    [10] Malik Sallam, Kholoud Al-Mahzoum, Lujain Alkandari, Aisha Shabakouh, Asmaa Shabakouh, Abiar Ali, Fajer Alenezi, Muna Barakat . Descriptive analysis of TikTok content on vaccination in Arabic. AIMS Public Health, 2025, 12(1): 137-161. doi: 10.3934/publichealth.2025010
  • The modern success story of vaccinations involves a historical chain of events that transformed the discovery that vaccines worked, to administering them to the population. We estimate the number of lives saved and morbidity reduction associated with the discovery of the first human cell strain used for the production of licensed human virus vaccines, known as WI-38. The diseases studied include poliomyelitis, measles, mumps, rubella, varicella (chicken pox), herpes zoster, adenovirus, rabies and Hepatitis A. The number of preventable cases and deaths in the U.S. and across the globe was assessed by holding prevalence rates and disease-specific death rates constant from 1960–2015. Results indicate that the total number of cases of poliomyelitis, measles, mumps, rubella, varicella, adenovirus, rabies and hepatitis A averted or treated with WI-38 related vaccines was 198 million in the U.S. and 4.5 billion globally (720 million in Africa; 387 million in Latin America and the Caribbean; 2.7 billion in Asia; and 455 million in Europe). The total number of deaths averted from these same diseases was approximately 450,000 in the U.S., and 10.3 million globally (1.6 million in Africa; 886 thousand in Latin America and the Caribbean; 6.2 million in Asia; and 1.0 million in Europe).


    Stigmatization of persons living with obesity, attributed to weight bias, is increasingly recognized as an important public health issue, but one that has received relatively little attention until recently [1]. Weight bias is comprised of negative attitudes and beliefs about a person based on body weight [2]. Misconceptions about the causes and consequences of obesity are perpetuated by beliefs that obesity is a direct result of a lack of self-control with regards to eating and exercise behaviors and that body weight reduction is directly associated with improved health and well-being [3]. Obesity stigma is typically defined as the manifestation of weight bias through harmful social stereotypes that are associated with people living with obesity, and that are widely held societally, including among health care providers [4]. Bias and stigma are associated with negative mental and physical health as reported by children and adults living with obesity [5][8]. Simply put, obesity stigma is now understood to be harmful to health but remains prevalent and intractable [9]. In October 2019, the annual report of Canada's Chief Public Health Officer focused on different forms of stigma, including obesity stigma, and called for health education institutions and professional associations to transform the practices, curricula, and professional competencies of health providers [10]. In March 2020, a joint international consensus statement for ending stigma of obesity was published, calling for academic institutions, professional organizations, media, public-health authorities, and governments to “encourage education about weight stigma to facilitate a new public narrative about obesity, coherent with modern scientific knowledge” [11].

    A multi-level, systems approach is required to reframe the prevailing stigmatizing narratives associated with obesity. Examples of strategies to reduce weight bias and stigma include adopting person-first language or terminology (i.e., people with obesity) instead of disease-first terminology (i.e., obese people, as well as other negative terms that people with obesity reject) and incorporating lived experiences of people living with obesity to promote empathy (i.e., people living with obesity are included in the research team or are provided with the opportunity to engage in research, practice or policy around obesity prevention or management) [12]. In 2008, the Board of Directors of Obesity Canada (formerly the Canadian Obesity Network, which was founded in 2006) identified reducing weight bias and obesity stigma as one of the network's top strategic priorities [13]. To this end, Obesity Canada began working towards reducing weight bias and obesity stigma through research, education and action. Activities to reduce weight bias and obesity stigma became an explicit focus across all network activities; the organization established a Public Engagement Committee to incorporate and amplify the lived experiences of people with obesity and three summits on weight bias and stigma were held [12],[14]. In 2015, the use of person-first language became a requirement in all documentation released by the organization [15]. These actions were strategic to advance Obesity Canada's mission to improve the lives of Canadians living with obesity through research, education and advocacy. In an effort to reduce weight bias and obesity stigma in the content of poster and oral presentations at the Canadian Obesity Summits, the use of person first language was included as part of the abstract submission guidelines for conference delegates attending the 2017 Canadian Obesity Summit (although this was not strictly enforced). The following is the original statement regarding person first language that was included in the abstract guidelines and remains in place today: “...People-first language is the standard for respectfully addressing people with chronic disease, rather than labelling them by their illness. Because of the importance of reducing bias associated with obesity, authors should not use ‘obese’ as an adjective or noun to describe and individual or group of people....”. Links to resources and examples of person-first language were provided for abstract authors.

    To date, the impact of this intentional shift in strategic focus to reduce weight bias and obesity stigma through the use of a person-first-language policy within Obesity Canada is unknown. The aim of this study was to conduct a qualitative content analysis of conference proceedings at Obesity Canada conferences, which comprised Canadian Obesity Summits (COS) and Canadian Obesity Student Meetings (COSM), to identify whether or how constructs that either promote or reduce weight bias and obesity stigma have changed over time in accepted abstracts, as a measure of whether or how biased terminology has changed. These two types of conferences are biennial conferences taking place alternating years. The COS are open to established researchers and trainees while the COSM are only open to trainees.

    We conducted a content analysis of conference proceedings for Obesity Canada's conferences from 2008–2019 to identify how constructs related to weight bias or stigma may have been incorporated within conference abstracts, as a measure of whether/how biased terminology may have changed over time. The unit of analysis for this study was abstracts (n = 1790) that were accepted for presentation at COS and COSM from 2008–2019. Abstracts accepted for the conferences underwent a two-step review process. First, abstracts were reviewed for significance and scientific merit by an independent scientific review committee and graded on a scale of 1 to 5. Comments from reviewers were encouraged during this review process with regards the quality of each abstract. Next, the top ranked abstracts were considered for specific conference sessions or themes by a smaller conference organizing committee. Lowest ranked abstracts were rejected, and the number of abstracts accepted varied according to the physical space available at different conference locations. The abstracts were reviewed to identify whether the use of constructs related to weight bias or stigma had changed over time. Because abstracts were accepted for presentation at conferences, they represent information that was available in the public domain and therefore ethical approval was not required. Only abstracts that featured human subjects were included (n = 1437). Abstracts which involved animal models or focused on cellular or genetic mechanisms were excluded (n = 353). A total of 1026 abstracts were from COS and 411 were from COSM. Abstracts were imported into Nvivo 12 for coding.

    Table 1.  Description of constructs of interest.
    Construct Positive Negative Why this is important
    Person-first terminology vs disease-first terminology used People/person with obesity; person living in a large(r) body Obese people/person; Use of negative terms that persons with obesity reject (e.g., chubby, morbidly obese, fat). The appropriate use of person-first terminology is a means of assessing how attitudes towards obesity may have shifted [15].
    Lived experience incorporated People with obesity are engaged in research/practice/policy. Persons with obesity are engaged in the conference/presentation and other knowledge translation activities. No lived experience inclusion; assumptions made by researcher/clinician. An indicator of weight bias is whether people with lived experiences are being engaged in research/education/policy etc. Engaging persons with obesity to reduce weight bias has been shown to have a positive effect (empathy). Engagement of persons affected by stigma is a strategy that has been used to reduce stigma in other communities (diabetes, mental illness, HIV/AIDS, LGTBQ+) [10].
    Weight bias/stigma Weight bias/stigma is mentioned or considered as an important issue to be addressed. Weight bias/stigma is ignored or negatively expressed (weight bias/stigma inappropriately used as a way to motivate behavior change in individuals). Implicit or explicit weight bias can be expressed in words or actions, e.g., by describing a person as an object (e.g., a 500 pounder) or through negative attributes (e.g., in relation to non-compliance, appearance or character traits). Stigma is the overt form of bias [10].
    Alarmist terminology Individuals living with obesity are strong, productive and valuable contributors to Canada. They deserve to be heard and demand to be included; decisions on treatment, care, prevention or policy must be person-centered. Obesity is a burden to the healthcare system and society. People with obesity are less productive, spend more healthcare dollars; The use of war metaphors in abstracts. The portrayal of obesity as a burden to society can lead to victim blaming and shaming; Persons with obesity are seen as a burden to society which contributes to weight bias/stigma [16],[17].
    Obesity as a modifiable risk factor vs obesity as a disease Obesity is a complex chronic disease that is the result of the interactions of genetic, metabolic, behavioral and environmental factors; Obesity prevention interventions move beyond healthy eating and physical activity. Obesity is not a chronic disease in itself but a risk factor for other chronic diseases; Obesity is caused mainly by modifiable behaviors (healthy eating and exercise).
    Healthy eating and physical activity interventions framed as obesity prevention strategies.
    The narrative that obesity is a self-inflicted behavioural choice drives weight bias attitudes and beliefs; Framing of obesity as a chronic disease can reduce weight bias [13],[18],[19].

     | Show Table
    DownLoad: CSV

    Content analysis is a form of thematic analysis that analyzes written, verbal or visual communication messages as a means to quantify certain phenomena [18]. Content analysis as a methodology has been applied to identify a broad range of phenomena, such as the most prevalent topics featured at an aging conference [20], gender messaging in parenting magazines [21] and children's food advertising [22]. It has also been successfully used to assess weight bias and stigma in a study by Heuer et al, that identified stigmatizing images across a range of media outlets [16]. Content analysis can be inductive (themes emerging from the data during the analysis process) or deductive (data analyzed using pre-determined categories based on what the research is designed to achieve) [18]. In this context, we applied a deductive analytical approach to assess whether there was a change (increase or decrease) in the appearance of five constructs of relevance to weight bias/stigma reduction over time. These constructs were agreed a priori by the authors as reflective of biased language and were 1) the use of person-first versus disease-first terminology; 2) the incorporation of lived experience in the work being described in the abstract; 3) whether weight bias or stigma is mentioned or considered as an important issue to be addressed; 4) the use of alarmist terminology to describe people living with obesity, and 5) language around whether obesity is viewed as a modifiable risk factor or as a disease. Table 1 provides a more detailed description of the constructs of interest. Each abstract was reviewed independently by two authors or research assistants with oversight by authors SFLK and MF. Discrepancies in coding were resolved through discussion. We calculated: 1) the overall frequency of use of each construct over time as a proportion of the total number of abstracts reviewed, and 2) the ratio of abstracts in which the construct appeared at least once based on the total number of abstracts, which accounts for a construct appearing multiple times within an abstract. Linear regression analyses were performed using Microsoft Excel to identify any correlations between these two measures and conference year.

    Table 2 shows the frequency and ratio of use of the relevant constructs in abstracts over time for all conferences, while Table 3 provides the ratio of abstracts where the construct appeared at least once relative to the total number of abstracts. From these it can be seen that there was a significant positive correlation between the use of person-first language in abstracts and time across both conference types and a corresponding negative correlation for the use of disease-first terminology. There was a significant positive correlation between mentions of weight bias and time. These significant effects remained when analyzed separately among COS abstracts, but only disease-first terminology remained significantly negatively correlated in the COSM abstracts. The frequency of abstracts that included or reported on lived experiences of obesity appeared to be low and did not vary over time in overall conference types or in sub-types (i.e., COS versus COSM). No significant trends were seen over time for use of alarmist terminology or framing of obesity as a disease or modifiable risk factor when considered as a ratio of the construct relative to the total number of abstracts. Figures 1 and 2 show the frequency and ratio of person-first, disease-first and weight bias constructs over time. Frequency of person-first and weight bias construct use increased significantly from 2015/2016 onwards, when person-first language became a requirement, initially in 2015 for all documents released by the organization and in 2017 when the requirement was applied to conference abstracts as a condition of acceptance.

    Figure 1.  Frequency of use of person-first, disease-first and weight-bias constructs over time.
    Figure 2.  Ratio of person-first, disease-first and weight-bias constructs over time.
    Table 2.  Frequency (ratio) of construct use over time (all conferences).
    Year Total no. of abstracts accepted (% of total) Person-first terminology used Disease-first terminology used Lived experience incorporated Weight-bias mentioned or considered Alarmist terminology used Obesity framed as disease Obesity framed as a modifiable risk factor
    2008 91 (na*) 6 (0.13) 39 (1.18) 0 (0.00) 0 (0.00) 7 (0.09) 0 (0.00) 11 (0.13)
    2009 107 (83%) 10 (0.15) 34 (0.86) 3 (0.03) 0 (0.00) 14 (0.16) 4 (0.04) 10 (0.09)
    2010 96 (89%) 8 (0.27) 39 (1.42) 1 (0.01) 2 (0.02) 5 (0.11) 4 (0.04) 13 (0.24)
    2011 217 (79%) 17 (0.12) 75 (1.27) 6 (0.04) 6 (0.08) 19 (0.15) 6 (0.05) 28 (0.20)
    2012 57 (90%) 3 (0.12) 19 (0.75) 0 (0.00) 1 (0.04) 2 (0.04) 0 (0.00) 1 (0.02)
    2013 196 (80%) 25 (0.32) 76 (1.72) 3 (0.03) 7 (0.10) 13 (0.11) 2 (0.01) 15 (0.10)
    2014 74 (95%) 7 (0.24) 16 (0.68) 0 (0.00) 3 (0.27) 3 (0.05) 1 (0.03) 9 (0.19)
    2015 233 (90%) 21 (0.23) 56 (0.99) 13 (0.07) 16 (0.23) 19 (0.10) 8 (0.01) 18 (0.09)
    2016 36 (na*) 5 (0.17) 12 (0.69) 0 (0.00) 0 (0.00) 0 (0.00) 11 (0.22) 0 (0.00)
    2017 138 (96%) 33 (0.55) 21 (0.28) 4 (0.04) 7 (0.14) 1 (0.01) 0 (0.00) 2 (0.01)
    2018 57 (93%) 21 (1.02) 7 (0.40) 3 (0.09) 8 (0.77) 8 (0.18) 8 (0.14) 11 (0.28)
    2019 135 (70%) 56 (1.81) 15 (0.27) 4 0.05) 14 (0.14) 3 (0.02) 28 (0.21) 4 (0.05)
    R2 value 0.51 0.48 0.31 0.53 0.16 0.35 0.04
    P value <0.01 =0.01 NS <0.01 NS <0.05 NS
    F value 10.56 9.41 4.44 11.47 1.88 5.51 0.40
    df 11 11 11 11 11 11 11

    *Note: Acceptance rates were not available for these two years. In 2008, the review committee was organized by the host institution and in 2016, the conference was run in conjunction with the International Congress on Obesity (ICO) which coordinated abstract review for both ICO and COSM.

     | Show Table
    DownLoad: CSV
    Table 3.  Ratio of construct use over time (all conferences) as a proportion of all abstracts.
    Year Person-first terminology used Disease-first terminology used Lived experience incorporated Weight-bias mentioned or considered Alarmist terminology used Obesity framed as disease Obesity framed as a modifiable risk factor
    2008 0.07 0.43 0 0 0.08 0 0.12
    2009 0.09 0.32 0.03 0 0.13 0.04 0.09
    2010 0.08 0.41 0.01 0.02 0.05 0.04 0.14
    2011 0.08 0.35 0.03 0.03 0.09 0.03 0.13
    2012 0.05 0.33 0 0.02 0.04 0 0.02
    2013 0.13 0.39 0.02 0.04 0.07 0.01 0.08
    2014 0.09 0.22 0 0.04 0.04 0.01 0.12
    2015 0.09 0.24 0.06 0.07 0.08 0.03 0.08
    2016 0.14 0.33 0 0 0 0 0
    2017 0.24 0.15 0.03 0.05 0.01 0.04 0.01
    2018 0.37 0.12 0.05 0.14 0.14 0 0.19
    2019 0.41 0.11 0.03 0.1 0.02 0.09 0.03
    R2 value 0.65 0.74 0.17 0.57 0.12 0.07 0.09
    P value <0.05 <0.001 NS <0.01 NS NS NS
    F value 18.73 28.37 2.00 13.30 1.34 0.77 1.01
    df 11 11 11 11 11 11 11

     | Show Table
    DownLoad: CSV

    In this analysis, we sought to assess the impact of Obesity Canada's intentional shift in strategic focus to reduce weight bias and obesity stigma among members and the wider research and clinical practice communities. Our findings suggest that there has been a shift in the constructs of interest, which in turn points to a change in terminology around how people with obesity are described in research and clinical practice, along with increasing recognition of weight bias and stigma as constructs of relevance to the obesity discourse.

    Although we cannot assume causation given the study design, we can see trends towards more frequent use of person-first language and less frequent use of disease-first terminology, as well as a trend towards more mentions of weight bias as an important construct for study in abstracts accepted over time, as illustrated in Figures 1 and 2. We did not see any significant trends over time in relation to the use of alarmist terminology or the incorporation of lived experiences as defined in Table 1. These constructs were also more difficult to assess. For example, it was difficult to analyze the incorporation of lived experiences through reading the abstracts alone as it was not always clear if individuals living with obesity were study participants, included as authors of the abstract or part of the presentation team, or if their lived experience was relevant to the study or presentation. It is therefore possible that lived experience was a feature of a presentation even though it was not mentioned in the abstract.

    The increase in abstracts that incorporated person-first language from 2015 corresponds to the decision by Obesity Canada to require the use of person-first language in all documents released by the organization [15]. Although person-first language was a component of Obesity Canada's implicit, strategic focus from 2008, incorporating this explicitly into the abstract submission guidelines in 2017 appears to have led to increased compliance at the COS that year. It should be noted that in 2015, Obesity Canada also launched the Public Engagement Initiative which included the creation of a Public Engagement Committee composed of individuals living with obesity. In 2016, Obesity Canada's Board of Directors also decided to restructure the organization into a registered charity. The organization underwent a rebranding exercise, creating a new name (from Canadian Obesity Network to Obesity Canada), logo and mission statement which focused on improving the lives of Canadians affected by obesity. Since 2017, all of Obesity Canada's committees have added representation from people living with obesity. In 2018, Obesity Canada created a patient-centered obesity advocacy strategy, which has significantly increased the voices of people living with obesity in Canada. Furthermore, 2017 was also the year that the lived experiences of people living with obesity were more firmly embedded in the conference program as keynote talks starting off each day of the conference. Creating empathy has been identified as an important component to reduce weight-bias and stigma among health professionals [2].

    Strengths of this study are the application of a robust methodology to identify constructs of relevance to weight bias and stigma reduction. Other strengths are the inclusion of all relevant abstracts that were accepted to the two national and student conferences over an 11-year time frame and the consensus-driven process for assessing abstracts as a means to identify the constructs of interest. In terms of limitations, there is likely a time lag with respect to the type of research that was submitted to the conferences, something that has been identified in the knowledge translation literature [23]. Research presented at any given conference reflects research funded and/or conducted in the preceding years, which may not be sensitive to shifts in policy. It would be anticipated that continued monitoring for constructs of interest over future conferences would help overcome these limitations. Further research is needed to see if such a change in approach translates to decreases in weight biased attitudes and beliefs among the public and health professionals. Additionally, our analysis was confined to accepted abstracts rather than all submitted abstracts. The acceptance rate for COS abstracts averaged 83% over the study period (range 70–96%), while the acceptance rate for COSM abstracts was slightly higher at 92% (range 89–95%), as might be expected for a student-focused conference (Dawn Hatanaka, personal communication). While we cannot be sure that submitted abstracts differed from accepted ones with respect to the constructs of interest, this represents a high acceptance rate.

    Our findings suggest a need to more intentionally address weight bias and stigma through changing policy and practice and clearly communicating such changes [1]. Obesity Canada's strategic decision in 2008 provided an opportunity for such changes to take root. However, addressing obesity as a chronic disease and weight bias as a social determinant of health are two priorities that still need to be more firmly embedded in healthcare settings [14],[24],[25]. These changes take time to become adopted as standard practice and their adoption should continue to be monitored. For example, with the inclusion of a weight bias and stigma chapter in the 2020 Canadian Obesity Clinical Practice Guideline, Obesity Canada has reaffirmed the need to use person-first language in research, clinical practice and policy [26]. In 2018, the Canadian Obesity Advocacy Network, comprised of a group of diverse organizations, prioritized the need to reframe obesity as a chronic disease by having consistent messaging and using person-first language in organizational reports, messaging and education [27]. Some research has also shown that framing obesity as a disease is associated with lower weight bias in health professionals [28],[29] and the public [29]. In 2019, the Public Health Agency of Canada called on all Canadians to end multiple forms of stigma in our society, including obesity stigma [10].

    In this content analysis of abstracts accepted to a leading Canadian obesity conference series, we found that the use of person-first terminology increased, and the use of disease-first terminology decreased, in abstracts that were accepted following a change in strategic focus to explicitly reduce weight bias and stigma. Additionally, the number of accepted abstracts that included a discussion of weight bias at the conferences increased over time. These findings offer some indication that the setting of strategic priorities to reduce weight bias and stigma can be helpful, although similar actions across multiple settings may be necessary to further shift the prevailing stigmatizing narratives that remain prevalent in society.

    [1] Centers for Disease Control and Prevention. Measles Cases and Outbreaks. US Department of Health and Human Services. December 13, 2016. Available from: https://www.cdc.gov/measles/cases-outbreaks.html.
    [2] Centers for Disease Control, U.S. multi-state measles outbreak, December 2014–January 2015. Atlanta, GA: US Department of Health and Human Services, 2015. Available from: http://emergency.cdc.gov/han/han00376.asp.
    [3] Centers for Disease Control, Facts for Parents: Diseases and the Vaccines that Prevent Them. 2015. Available from: http://www.cdc.gov/vaccines/vpd-vac/fact-sheet-parents.html.
    [4] Orenstein WA, Douglas RG, Rodewald LE, et al. (2005) Immunizations in the United States: Success, Structure, and Stress. Health Aff 24: 599-610. doi: 10.1377/hlthaff.24.3.599
    [5] Every Child by Two, 2015. Available From: http://www.ecbt.org/images/articles/eBookOfDiseases.pdf.
    [6] Dubé E, Vivion M, MacDonald NE (2015) Vaccine hesitancy, vaccine refusal and the anti-vaccine movement: influence, impact and implications. Expert Rev Vaccines 14: 99-117. doi: 10.1586/14760584.2015.964212
    [7] Majumder MS, Cohn EL, Mekaru SR, et al. (2015) Substandard vaccination compliance and the 2015 Measles outbreak. JAMA Pediatr 169.
    [8] Hayflick L, Moorhead PS (1961) The serial cultivation of human diploid cell strains. Exp Cell Res 25: 585-621. doi: 10.1016/0014-4827(61)90192-6
    [9] Jacobs JP, Jones CM, Baille JP (1970) Characteristics of a human diploid cell designated MRC-5. Nature 227: 168-170. doi: 10.1038/227168a0
    [10] Riley JC (2001) Rising Life Expectancy: A Global History (Cambridge University Press, U.K.).
    [11] Riedel A (2005) Edward Jenner and the history of smallpox and vaccination, BUMC Proc 18: 21-25.
    [12] World Health Organization (2009) State of the World's Vaccines and Immunization (3rd Edition, Geneva).
    [13] Hayflick L (2001) In Evolving Scientific and Regulatory Perspectives on Cell Substrates for Vaccine Development, Brown F, Krause P, Lewis AM, Eds. (Karger, Basel), 106: 5-23.
    [14] Koprowski H, Ponten JA, Jensen F, et al. (1962) Transformation of cultures of human tissue infected with simian virus S.V. 40, J Cell Comp Physiol 59: 281. doi: 10.1002/jcp.1030590308
    [15] Bookchin D, Schumacher J (2004) The virus and the vaccine, St. Martin's Press NYC.
    [16] Hayflick L, Norton TW, Plotkin SA, et al. (1962) Preparation of poliovirus vaccines in a human fetal diploid cell strain. Am J Hyg 77: 240-258.
    [17] Hayflick L (1965) The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 37: 614-636. doi: 10.1016/0014-4827(65)90211-9
    [18] Hayflick L, Plotkin S, Stevenson RE (1987) In WHO Study Group on Cells, Products and Safety, Petricciani JC and Hennessen W Eds. (Karger, Basel), 68: 9-17.
    [19] Jacobs JP, Jones CM, Baille JP (1970) Characteristics of a human diploid cell designated MRC-5. Nature 227:168-70. doi: 10.1038/227168a0
    [20] Hayflick L (1989) In Developments in Biological Standardization, Continuous Cell Lines as Substrates for Biologicals, Proceedings of the International Association of Biological Standardization, L. Hayflick, W. Hennessen, S. Karger AG, Basel, Eds. Basel, Switzerland, 70: 11-26.
    [21] Roush MT, Murphy TV, and the Vaccine-Preventable Disease Table Working Group (2007) Historical Comparisons of Morbidity and Mortality for Vaccine-Preventable Diseases in the United States. JAMA 298: 2155-2163, doi:10.1001/jama.298.18.2155.
    [22] Banatvala J, Peckham C (2007) In Rubella Viruses, Perspectives in Medical Virology, A.J. Zuckerman, I.K. Mushahwar, Eds. (Elsevier), vol. 15, p.xi, Table 1.
    [23] Wakefield AJ, Murch SH, Anthony A, et al. (1998) Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 351: 637-641. doi: 10.1016/S0140-6736(97)11096-0
    [24] Godlee F, Smith J, Marcovitch H (2011) Wakefield's article linking MMR vaccine and autism was fraudulent. BMJ 342: C6452.
    [25] Smith PJ, Humiston SG, Marcuse EK, et al. (2011) Parental delay or refusal of vaccine doses, childhood vaccination coverage at 24 months of age, and the Health Belief Model. Public Health Rep 126: 135-146. doi: 10.1177/00333549111260S215
    [26] Bloom DE, Canning D (2001) The health and wealth of nations (2000) Science 287: 1207, 1209.
    [27] Plotkin S, Rubella eradication (2001) Vaccine 19: 3311-3319.
    [28] California Legislative Information, SB-277 Public Health: Vaccinations, 2015. Available From: https://leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill_id=201520160SB277.
  • This article has been cited by:

    1. Rana Nikzad, Laura S. Angelo, Kevin Aviles-Padilla, Duy T. Le, Vipul K. Singh, Lynn Bimler, Milica Vukmanovic-Stejic, Elena Vendrame, Thanmayi Ranganath, Laura Simpson, Nancy L. Haigwood, Catherine A. Blish, Arne N. Akbar, Silke Paust, Human natural killer cells mediate adaptive immunity to viral antigens, 2019, 4, 2470-9468, eaat8116, 10.1126/sciimmunol.aat8116
    2. Alexis Laurent, Nathalie Hirt-Burri, Corinne Scaletta, Murielle Michetti, Anthony S. de Buys Roessingh, Wassim Raffoul, Lee Ann Applegate, Holistic Approach of Swiss Fetal Progenitor Cell Banking: Optimizing Safe and Sustainable Substrates for Regenerative Medicine and Biotechnology, 2020, 8, 2296-4185, 10.3389/fbioe.2020.557758
    3. Hung Wei Lai, Ryuta Sasaki, Shiro Usuki, Motowo Nakajima, Tohru Tanaka, Shun-ichiro Ogura, Novel strategy to increase specificity of ALA-Induced PpIX accumulation through inhibition of transporters involved in ALA uptake, 2019, 27, 15721000, 327, 10.1016/j.pdpdt.2019.06.017
    4. Clementina Sansone, Christian Galasso, Marco Lo Martire, Tomás Vega Fernández, Luigi Musco, Antonio Dell’Anno, Antonino Bruno, Douglas M. Noonan, Adriana Albini, Christophe Brunet, In Vitro Evaluation of Antioxidant Potential of the Invasive Seagrass Halophila stipulacea, 2021, 19, 1660-3397, 37, 10.3390/md19010037
    5. George F Winter, Vaccines and the fetus, 2018, 26, 0969-4900, 480, 10.12968/bjom.2018.26.7.480
    6. Alexis Laurent, Poyin Lin, Corinne Scaletta, Nathalie Hirt-Burri, Murielle Michetti, Anthony S. de Buys Roessingh, Wassim Raffoul, Bin-Ru She, Lee Ann Applegate, Bringing Safe and Standardized Cell Therapies to Industrialized Processing for Burns and Wounds, 2020, 8, 2296-4185, 10.3389/fbioe.2020.00581
    7. Anthony R. Mawson, Ashley M. Croft, Multiple Vaccinations and the Enigma of Vaccine Injury, 2020, 8, 2076-393X, 676, 10.3390/vaccines8040676
    8. Leonard Hayflick, Subject of The Vaccine Race offers perspective on errors, 2018, 392, 01406736, 633, 10.1016/S0140-6736(18)31648-9
    9. Steve Campbell, Elaine Crisp, Commentary: Vaccine-hesitant parents’ reasons for choosing alternate protection methods in Turkey, 2020, 1744-9871, 174498712097129, 10.1177/1744987120971292
    10. llya Soifer, Nicole L Fong, Nelda Yi, Andrea T Ireland, Irene Lam, Matthew Sooknah, Jonathan S Paw, Paul Peluso, Gregory T Concepcion, David Rank, Alex R Hastie, Vladimir Jojic, J Graham Ruby, David Botstein, Margaret A Roy, Fully Phased Sequence of a Diploid Human Genome Determined de Novo from the DNA of a Single Individual, 2020, 10, 2160-1836, 2911, 10.1534/g3.119.400995
    11. George Winter, Vaccines and anti-vaccination, 2020, 2, 2631-8385, 378, 10.12968/jprp.2020.2.7.378
    12. Alexis Laurent, Corinne Scaletta, Philippe Abdel-Sayed, Murielle Michetti, Anthony de Buys Roessingh, Wassim Raffoul, Nathalie Hirt-Burri, Lee Ann Applegate, Biotechnology and Cytotherapeutics: The Swiss Progenitor-Cell Transplantation Program, 2022, 2, 2673-8392, 336, 10.3390/encyclopedia2010021
    13. Amanda M. Bifani, Hwee Cheng Tan, Milly M. Choy, Eng Eong Ooi, Susana López, Cell Strain-Derived Induced Pluripotent Stem Cells as an Isogenic Approach To Investigate Age-Related Host Response to Flaviviral Infection, 2022, 96, 0022-538X, 10.1128/jvi.01737-21
    14. Alexis Laurent, Philippe Abdel-Sayed, Corinne Scaletta, Philippe Laurent, Elénie Laurent, Murielle Michetti, Anthony de Buys Roessingh, Wassim Raffoul, Nathalie Hirt-Burri, Lee Ann Applegate, Back to the Cradle of Cytotherapy: Integrating a Century of Clinical Research and Biotechnology-Based Manufacturing for Modern Tissue-Specific Cellular Treatments in Switzerland, 2021, 8, 2306-5354, 221, 10.3390/bioengineering8120221
    15. Yu-Hsiu Chen, Xin Zhang, Kuei-Yueh Ko, Ming-Feng Hsueh, Virginia Byers Kraus, Milena Georgieva, CBX4 Regulates Replicative Senescence of WI-38 Fibroblasts, 2022, 2022, 1942-0994, 1, 10.1155/2022/5503575
    16. Iver Petersen, Classification and Treatment of Diseases in the Age of Genome Medicine Based on Pathway Pathology, 2021, 22, 1422-0067, 9418, 10.3390/ijms22179418
    17. Patrick M. Perrigue, Agata Henschke, Bartosz F. Grześkowiak, Łucja Przysiecka, Kaja Jaskot, Angelika Mielcarek, Emerson Coy, Sergio E. Moya, Cellular uptake and retention studies of silica nanoparticles utilizing senescent fibroblasts, 2023, 13, 2045-2322, 10.1038/s41598-022-26979-1
    18. Veysel Kayser, Iqbal Ramzan, Vaccines and vaccination: history and emerging issues, 2021, 17, 2164-5515, 5255, 10.1080/21645515.2021.1977057
    19. Alexis Laurent, Corinne Scaletta, Philippe Abdel-Sayed, Wassim Raffoul, Nathalie Hirt-Burri, Lee Ann Applegate, Primary Progenitor Tenocytes: Cytotherapeutics and Cell-Free Derivatives, 2023, 3, 2673-8392, 340, 10.3390/encyclopedia3010021
    20. Mark T. Menghini, Christoph Geisler, Ajay B. Maghodia, Hoai J. Hallam, Steven L. Denton, Jason P. Gigley, Donald L. Jarvis, Host ranges of Sf-rhabdoviruses harbored by lepidopteran insects and insect cell lines, 2023, 00426822, 10.1016/j.virol.2023.05.007
    21. Justin Brumbaugh, Brian A. Aguado, Tamra Lysaght, Lawrence S.B. Goldstein, Human fetal tissue is critical for biomedical research, 2023, 22136711, 10.1016/j.stemcr.2023.10.008
    22. Maria Knoth Humlum, Marius Opstrup Morthorst, Peter Rønø Thingholm, Sibling spillovers and the choice to get vaccinated: Evidence from a regression discontinuity design, 2023, 01676296, 102843, 10.1016/j.jhealeco.2023.102843
    23. Natalya Eshchenko, Mariia Sergeeva, Evgenii Zhuravlev, Kira Kudria, Elena Goncharova, Andrey Komissarov, Grigory Stepanov, A Knockout of the IFITM3 Gene Increases the Sensitivity of WI-38 VA13 Cells to the Influenza A Virus, 2024, 25, 1422-0067, 625, 10.3390/ijms25010625
    24. Bruno Vinicius Santos Valiate, Julia Teixeira de Castro, Tomás Gazzinelli Marçal, Luis Adan Flores Andrade, Livia Isabela de Oliveira, Gabriela Barbi Freire Maia, Lídia Paula Faustino, Natalia S. Hojo-Souza, Marconi Augusto Aguiar Dos Reis, Flávia Fonseca Bagno, Natalia Salazar, Santuza R. Teixeira, Gregório Guilherme Almeida, Ricardo Tostes Gazzinelli, Evaluation of an RBD-nucleocapsid fusion protein as a booster candidate for COVID-19 vaccine, 2024, 27, 25890042, 110177, 10.1016/j.isci.2024.110177
    25. Michael D. West, João Pedro de Magalhães, S. Jay Olshansky, Leonard Hayflick (1928–2024), 2024, 2662-8465, 10.1038/s43587-024-00720-1
    26. Manuel Serrano, Leonard Hayflick (1928-2024) – obituary, 2024, 10, 2731-6068, 10.1038/s41514-024-00174-0
    27. Mahmoud S. Elkotamy, Islam A. Elkelesh, Simone Giovannuzzi, Rania S.M. Ismail, Wessam M. El-Refaie, Abdulrahman A. Almehizia, Ahmed M. Naglah, Alessio Nocentini, Claudiu T. Supuran, Mohamed Fares, Hazem A. Ghabbour, Rofaida Salem, Wagdy M. Eldehna, Hatem A. Abdel-Aziz, Rationally Designed Pyrazolo[1,5-a]pyrimidines as Dual Inhibitors of CA IX/XII and CDK6: A Novel Approach for NSCLC Treatment, 2025, 02235234, 117752, 10.1016/j.ejmech.2025.117752
    28. Aviraj K. S, Apoorva Wasnik, Lalima Gupta, Ayushi Ranjan, Harshini Suresh, Effectiveness of interventions to improve vaccine efficacy: a systematic review and meta-analysis, 2025, 14, 2046-4053, 10.1186/s13643-025-02856-6
  • Reader Comments
  • © 2017 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(22566) PDF downloads(2437) Cited by(28)

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog